The estimated Net Worth of John P. Kenny is at least $17.5 Million dollars as of 24 June 2022. Mr Kenny owns over 74,996 units of Meridian Bioscience stock worth over $11,093,515 and over the last 7 years he sold VIVO stock worth over $4,939,280. In addition, he makes $1,508,705 as Pres und CEO & Director at Meridian Bioscience.
Sign up
Mr Kenny VIVO stock SEC Form 4 insiders trading
Mr has made over 12 trades of the Meridian Bioscience stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 74,996 units of VIVO stock worth $757,460 on 24 June 2022.
The largest trade he's ever made was exercising 74,996 units of Meridian Bioscience stock on 24 June 2022 worth over $757,460. On average, Mr trades about 15,298 units every 44 days since 2017. As of 24 June 2022 he still owns at least 326,568 units of Meridian Bioscience stock.
You can see the complete history of Mr Kenny stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. John P. Kenny biography
John P. Kenny is the Pres, CEO & Director at Meridian Bioscience.
What is the salary of Mr Kenny?
As the Pres und CEO & Director of Meridian Bioscience, the total compensation of Mr Kenny at Meridian Bioscience is $1,508,705. There are no executives at Meridian Bioscience getting paid more.
How old is Mr Kenny?
Mr Kenny is 53, he's been the Pres und CEO & Director of Meridian Bioscience since . There are 11 older and 1 younger executives at Meridian Bioscience. The oldest executive at Meridian Bioscience Inc. is David Phillips, 81, who is the Independent Chairman of the Board.
What's Mr Kenny's mailing address?
John's mailing address filed with the SEC is C/O ORASURE TECHNOLOGIES, INC., 220 EAST FIRST STREET, BETHLEHEM, PA, 18015.
Insiders trading at Meridian Bioscience
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny und John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
What does Meridian Bioscience do?
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
What does Meridian Bioscience's logo look like?
Complete history of Mr Kenny stock trades at Biomerica, Meridian Bioscience und Orasure Technologies
Meridian Bioscience executives and stock owners
Meridian Bioscience executives and other stock owners filed with the SEC include:
-
John P. Kenny,
Pres, CEO & Director -
John Kenny,
Chief Executive Officer, Director -
Lourdes Weltzien,
Executive Vice President - Life Science -
Dr. Lourdes G. Weltzien Ph.D.,
Exec. VP of Life Science Bus. Unit -
Tony Serafini-Lamanna,
Exec. VP of Diagnostics -
Bryan Baldasare,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer -
David Phillips,
Independent Chairman of the Board -
James Anderson,
Independent Director -
Dwight Ellingwood,
Independent Director -
Felicia Williams,
Independent Director -
Catherine Sazdanoff,
Independent Director -
John Rice,
Independent Director -
John McIlwraith,
Independent Director -
Anthony Bihl,
Independent Director -
Melissa A. Lueke,
Consultant -
Susan D. Rolih,
Consultant -
Melissa J. McCarey,
VP of Global HR -
Charles Wood,
VP of Investor Relations -
Jeff Pinkston,
Director of Corp. Fin. -
Julie Smith,
Sr. VP, Controller & Principal Accounting Officer -
Michael C. Shaughnessy,
EVP, Pres Meridian Global Dx -
Amy Winslow,
EVP, Pres & CEO of Magellan -
Melissa Lueke,
Exec VP, CFO -
Marco G. Calzavara,
Pres & Managing Director, MBE -
Vecheslav A Elagin,
Sr VP, Research & Development -
Eric S. Rasmussen,
EVP, Bus. Development/Strategy -
Kenneth Kozak,
Vice President -
Susan Rolih,
EVP, Reg & Quality Systems -
Lawrence Baldini,
VP, Operations -
Robert J Ready,
Director -
Marviette D. Johnson,
VP, Human Resources -
Todd W Motto,
VP, Sales and Marketing -
Grady Barnes,
VP, Research & Development -
Gregory S Ballish,
VP, Sales and Marketing -
James Buzard,
Director -
Richard Eberly,
Ex. VP, Gen Mgr. Mer. Life Sci -
Gary P Kreider,
Director -
Vivo Family Limited Partner...,
10% owner -
William J Motto,
Chairman, CEO -
Antonio Interno,
Senior Vice President -
John A Kraeutler,
Chairman and CEO -
Tony Serafini Lamanna,
Executive VP-Diagnostics